Huntington's Disease Market Future Scope, Opportunities with Strategic Growth and Top Players Forecast 2022-2031

New York, Global Huntington's Disease Market report from Global Insight Services is the single authoritative source of intelligence on Huntington's Disease Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.

Read more about Huntington's Disease Market here: https://www.globalinsightservices.com/reports/huntingtons-disease-market/

Huntington's disease is a neurodegenerative disorder caused by a mutation in the HTT gene. This gene provides instructions for making a protein called huntingtin. Huntingtin is involved in the development and function of neurons in the brain. The HTT gene mutation causes an abnormal expansion of a section of DNA called CAG repeats. This expansion leads to the production of an abnormally long huntingtin protein. The abnormal huntingtin protein interferes with the normal functioning of neurons and causes the death of these cells.

Download a Free PDF Sample Copy of Report - https://www.globalinsightservices.com/request-sample/GIS10115/

Key Trends

In the past decade, there have been significant advances in our understanding of Huntington's disease (HD), paving the way for new treatments. The HD market is currently small, but is expected to grow as more treatments are approved and awareness of the disease increases.

The most notable recent development in HD is the approval of the first ever therapeutic drug, Spinraza (nusinersen), in December 2016. Spinraza is an antisense oligonucleotide that targets the mutated huntingtin protein and has been shown to improve motor function and delay disease progression in clinical trials. This is a major breakthrough for HD patients and their families, and is expected to drive growth in the HD market in the coming years.

Other key trends in the HD market include:

Increasing awareness of the disease. In the past, HD was often misdiagnosed or not diagnosed at all, due to its similarity to other neurological conditions.
Improved diagnosis and treatment options. In addition to Spinraza, there are a number of other promising HD treatments in development, including small molecule drugs, gene therapy, and stem cell therapy. These new treatments are expected to improve HD patient's quality of life and extend their life expectancy.
Growing prevalence of HD. HD is a progressive, degenerative disease with no cure. The number of people affected by HD is expected to increase as the population ages and the average life expectancy increases.
Increasing costs of HD care. HD is a complex disease that requires lifelong treatment. The costs of HD care are expected to increase as more treatments are approved and the number of people affected by HD grows.

Key Drivers

There are a number of key drivers of the Huntington's disease market.

Firstly, the increasing prevalence of the condition is a key driver. Huntington's disease is a progressive neurodegenerative disorder that typically affects people in their 30s or 40s. The condition is characterized by a number of symptoms including involuntary movements, cognitive decline, and psychiatric problems. The prevalence of Huntington's disease is thought to be around 5-10 per 100,000 people.

Secondly, the development of new treatments is a key driver of the Huntington's disease market. There are a number of new treatments in development that are showing promise in clinical trials. These new treatments are aimed at slowing the progression of the disease and improving the quality of life for patients.

Get Customized report as per your requirements - https://www.globalinsightservices.com/request-customization/GIS10115/

Market Segments

By Treatment
Symptomatic treatment
Disease-Modifying Therapies

Key Players

-AbbVie
-Acorda Therapeutics
-Amgen
-BioMarin Pharmaceutical
-F. Hoffmann-La Roche
-Ionis Pharmaceuticals
-Janssen Pharmaceuticals
-Pfizer
-Sanofi

Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS10115/

With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.